Abstracts tagged "infliximab"

Abstract Number: 19L • 2016 ACR/ARHP Annual Meeting
Biosimilar Infliximab (CT-P13) Is Not Inferior to Originator Infliximab: Results from a 52-Week Randomized Switch Trial in Norway
Guro Løvik Goll^1,2, Inge C Olsen³, Kristin K Jorgensen⁴, Merete Lorentzen⁵, Nils Bolstad⁶, Espen A. Haavardsholm⁷, Knut EA Lundin⁸, Cato Mork⁹, Jorgen Jahnsen⁴, Tore K Kvien³ and the NOR-SWITCH study group, ¹Dept of Rheumatoogy, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumathology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept of Gastroenterology, Akershus University Hospital, Lorenskog, Norway, ⁵Dept of Dermatology, Rikshospitalet, Oslo, Norway, ⁶Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, ⁷Diakonhjemmet Hospital, Oslo, Norway, ⁸Dept of gastroenterology, Rikshospitalet, Oslo, Norway, ⁹Dept of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: TNF-inhibitors (TNFi) have improved treatment of spondyloarthritis (SpA), rheumatoid arthritis (RA), psoriatic arthritis (PsA), Crohn’s disease (CD), ulcerative colitis (UC), and chronic plaque…
Abstract Number: 627 • 2016 ACR/ARHP Annual Meeting
Clinical and Immunogenicity Outcomes after Switching Treatment from Innovator Infliximab to Biosimilar Infliximab in Rheumatic Diseases in Daily Clinical Practice
L Tweehuysen¹, B.J.F. van den Bemt², I.L. van Ingen³, A.J.L. de Jong⁴, W.H. van der Laan⁵, F.H.J. van den Hoogen⁵ and A.A. den Broeder⁵, ¹Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, ²Pharmacy, Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, ³Rheumatology, Radboudumc Nijmegen, Nijmegen, Netherlands, ⁴Department of Rheumatology, Rijnstate Arnhem, Arnhem, Netherlands, ⁵Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Biosimilar infliximab is registered in Europe for the same therapeutic indications as innovator infliximab. In 2015, four rheumatology departments in the Netherlands decided to…
Abstract Number: 630 • 2016 ACR/ARHP Annual Meeting
Strategies for Biological Drug Quantification in Biological Drug Immune Responses
Michael Kruse Meyer^1,2, Marlene Andersen^1,3, Troels Vindbæk Stausbo⁴, Tue Bjerg Bennike^4,5, Grethe Neumann Andersen^1,6 and Allan Stensballe^3,4, ¹Department of Rheumatology, North Denmark Regional Hospital, Hjørring, Denmark, ²Laboratory for Medical Mass Spectrometry, Aalborg University, Aalborg, Denmark, ³Department of Health Science and Technology, Aalborg University, Aalborg, Denmark, ⁴Laboratory of Medical Mass Spectrometry, Aalborg University, Aalborg, Denmark, ⁵Research Unit for Molecular Diagnostic and Clinical Research, Harvard Medical School, Boston, MA, ⁶Center for Clinical Science, Aalborg University, Hjørring, Denmark
Background/Purpose: The development of the biological DMARDs has benefitted patients, who previously had no treatment options. Currently no method for stratifying patients to these drugs…
Abstract Number: 689 • 2016 ACR/ARHP Annual Meeting
Relationship Between Infliximab Serum Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis
Theodora Bejan-Angoulvant¹, David Ternant², Fadela Daoued³, Frédéric Medina³, Louis Bernard⁴, Saloua Mammou³, Gilles Paintaud² and Denis Mulleman⁵, ¹Service de Pharmacologie Clinique, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, ²Laboratoire de Pharmacologie-Toxicologie, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, ³Service de Rhumatologie, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, ⁴Service des Maladies Infectieuses, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, ⁵Service de Rhumatologie, Rheumatology department, François-Rabelais University, CNRS 7292, CHRU de Tours, Tours, France
Background/Purpose: Tumour necrosis factor alpha inhibitors are effective in reducing inflammation in rheumatic diseases while increasing the risk of infections. We aimed to study the…
Abstract Number: 1122 • 2016 ACR/ARHP Annual Meeting
Infliximab Suppresses the Monocyte Chemotaxis in Human TNF-Transgenic Mice
Qi Quan Huang¹, Robert Birkett¹, Elyssa L Roberts² and Richard M. Pope³, ¹Medicine/Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL, ²northwestern University, Chicago, IL, ³Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Macrophages in rheumatoid arthritis (RA) synovium produce high levels of inflammatory cytokines/chemokines and play the pivotal role in promoting inflammation and joint destruction. Treatment…
Abstract Number: 1337 • 2016 ACR/ARHP Annual Meeting
Effectiveness of Certolizumab Pegol in Patients with Uveitis Refractory to Other Tumor Necrosis Factor Inhibitors. Report of 22 Cases
M. Victoria Hernández¹, Marina Mesquida², Victor Llorens², Maite Sainz de la Maza², Gerard Espinosa³, Ricardo Blanco⁴, Vanesa Calvo⁴, Olga Maiz⁵, Ana Blanco⁶, Juan Ramon De Dios⁷, Pilar Ahijado-Guzman⁸, Enrique Judez⁹, Patricia Tejón¹⁰, M Soledad Peña¹¹, Raimon Sanmarti¹ and Alfredo Adan¹², ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Ophthalmology Department. Hospital Clínic de Barcelona, Barcelona, Spain, ³Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Rheumatology Department. Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Rheumatology Department. Donostia University Hospital, San Sebastian, Spain, ⁶Ophthalmology Department. Donostia University Hospital, Donostia, Spain, ⁷Rheumatology, Hospital Universitario de Araba, Vitoria, Spain, ⁸Avda. Reyes Catolicos, 21, Rheumatology Department. Hospital Infanta Elena, Valdemoro, Madrid, Spain, ⁹Rheumatology Department. Hospital de Albacete, Albacete, Spain, ¹⁰Rheumatology Department. Hospital Universitario General de Castellón, Castellon, Spain, ¹¹Ophtalmology Dpt. Hospital Universitario General de Castellón, Castellon, Spain, ¹²Ophthalmology, Ophthalmology Department. Hospital Clínic de Barcelona, Barcelona, Spain
Background/Purpose: Refractory uveitis may requiere the use of biological therapy, especially tumour necrosis factors inhibitors (TNFi), being the most currently used infliximab and adalimumab. However,…
Abstract Number: 1730 • 2016 ACR/ARHP Annual Meeting
Disease Progression Among Non-Achievers of Minimal Disease Activity in Psa Patients Treated with Infliximab or Golimumab
Dalton Sholter¹, Proton Rahman², Maqbool Sheriff³, Michel Zummer⁴, Suneil Kapur⁵, Philip Baer⁶, Michael Starr⁷, John Kelsall⁸, Emmanouil Rampakakis⁹, Eliofotisti Psaradellis¹⁰, Brendan Osborne¹¹, Karina Maslova¹², Cathy Tkaczyk¹¹, Francois Nantel¹³ and Allen J Lehman¹², ¹University of Alberta, Edmonton, AB, Canada, ²Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ³Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁴Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, ⁵University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ⁶Independent Rheumatology Practice, Scarborough, ON, Canada, ⁷Rheumatology, Mcgill University, Pointe-Claire,, QC, Canada, ⁸Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁹JSS Medical Research, St-Laurent, QC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose : Early achievement of minimal disease activity (MDA) is recommended as a valid treat-to-target approach in psoriatic arthritis (PsA). The purpose of the current…
Abstract Number: 2866 • 2015 ACR/ARHP Annual Meeting
Effectiveness and Safety of Golimumab in the Treatment of Psoriatic Arthritis over a 12 Month Period
Proton Rahman¹, Michel Zummer², William G Bensen³, Isabelle Fortin⁴, Dalton Sholter⁵, Milton F. Baker⁶, Regan Arendse⁷, Eliofotisti Psaradellis⁸, Emmanouil Rampakakis⁹, Francois Nantel¹⁰, Allen J Lehman¹⁰, Cathy Tkaczyk¹¹, Karina Maslova¹⁰ and Brendan Osborne¹¹, ¹Medicine, Memorial University, St John's, NF, Canada, ²Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁵Rheumatology Associates, Edmonton, AB, Canada, ⁶VIHA, Victoria, BC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹JSS Medical Research, St-Laurent, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The efficacy and tolerability of golimumab (GLM) in patients with psoriatic arthritis (PsA) has been demonstrated in several controlled clinical trials. Longitudinal observational studies…
Abstract Number: 2744 • 2015 ACR/ARHP Annual Meeting
What Is the Treatment Durability and Safety Profile of Rheumatoid Arthritis Patients Treated with Infliximab Plus Methotrexate and/or Leflunomide? an Analysis from a Real-World Registry
Rafat Faraawi¹, Raman Joshi², William G Bensen³, Denis Choquette⁴, Wojciech Olsynzynski⁵, Regan Arendse⁵, Maqbool Sheriff⁶, Proton Rahman⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Francois Nantel¹⁰, Allen J Lehman¹¹, Susan Otawa¹¹, Cathy Tkaczyk¹¹ and Brendan Osborne¹¹, ¹McMaster University, Hamilton, ON, Canada, ²William Osler Health Centre-Brampton Civic Hospital, Brampton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁵University of Saskatchewan, Saskatoon, ON, Canada, ⁶Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁷Medicine, Memorial University, St John's, NF, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Clinical trials of anti-TNF therapies have shown that concurrent methotrexate (MTX) therapy enhances the efficacy of TNF inhibitors. A scarcity of data exists on…
Abstract Number: 1302 • 2015 ACR/ARHP Annual Meeting
Inflammation Signs on Magnetic Resonance Imaging in Chronic or Recurrent Gonarthritis Treated with Intra-Articular Infliximab or Corticosteroids
Gülsah Akdemir¹, Arie E. van der Bijl², Badelog J.E. de Lange-Brokaar³, T. W. J. Huizinga¹, Cornelia F. Allaart¹ and Margreet Kloppenburg³, ¹Rheumatology, LUMC, Leiden, Netherlands, ²Isala Klinieken, Zwolle, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: To evaluate synovial inflammation on magnetic resonance imaging (MRI) before treatment and changes after treatment with intra-articular (i.a.) infliximab (IFX) or methylprednisolone (MP) injections…
Abstract Number: 1273 • 2015 ACR/ARHP Annual Meeting
Uptake of the First Biosimilar Infliximab Since Its Approval in South Korea
Seoyoung C. Kim¹, Nam-Kyong Choi², Joongyub Lee², Kyoung-Eun Kwon³, Wesley Eddings⁴, Yoon-Kyoung Sung⁵, Hong Ji Song⁶, Aaron K. Kesselheim⁴ and Daniel H. Solomon⁷, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Seoul National University Hospital, Seoul, South Korea, ³Seoul National University College of Medicine, Seoul, South Korea, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁵Hospital for Rheumatic Disease, Hanyang Univ Medical Center, Seoul, South Korea, ⁶Hallym University Sacred Heart Hospital, Anyang, South Korea, ⁷Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Development of tumor necrosis factor (TNF) inhibitors has been a major advance in treatment of systemic inflammatory diseases, such as rheumatoid arthritis. While TNF…
Abstract Number: 599 • 2015 ACR/ARHP Annual Meeting
An Examination of Dose Escalation Among Remicade (infliximab) Users in a US RA Registry
Jeffrey R. Curtis¹, Ying Shan², Joel M. Kremer³, Katherine Saunders⁴, Dennis Parenti⁵ and Shelly Kafka⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²UMass Memorial Medical Center, Worcester, MA, ³Albany Medical College, Albany, NY, ⁴Corrona LLC, Atlanta, GA, ⁵Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: Limited data are available about infliximab(IFX) dose escalation. This analysis examines the frequency of dose escalation among IFX patients using data from the US…
Abstract Number: 595 • 2015 ACR/ARHP Annual Meeting
Discovery of Serum Protein Biomarkers of Response to Adalimumab in Rheumatoid Arthritis and Their Relationship to Biomarkers of Response to Infliximab
Ignacio Ortea¹, Bernd Roschitzki², Eva Tomero³, Juan G. Ovalles-Bonilla⁴, Javier Lopez-Longo⁵, Inmaculada de la Torre⁵, Isidoro Gonzalez-Alvaro⁶, Juan J Gomez-Reino⁷ and Antonio Gonzalez⁸, ¹Maimónides Health Research Institute (IMIBIC), Cordoba, Spain, ²Functional Genomics Center Zurich, University and ETH Zurich, Zurich, Switzerland, ³Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁴Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵Gregorio Marañon Hospital, Madrid, Spain, ⁶Hospital Univ. de La Princesa, IIS Princesa, Madrid, Spain, ⁷Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁸Laboratorio Investigacion 10 and Rheumatology Unit, Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
Background/Purpose: Biomarkers of response to treatment in rheumatoid arthritis (RA) are sorely needed given the large inter-individual variability in efficacy of the available drugs. However,…
Abstract Number: 2763 • 2014 ACR/ARHP Annual Meeting
Long-Term Outcome of Chronic Progressive Neurological Manifestations in Behcet’s Disease
Shunsei Hirohata¹, Hirotoshi Kikuchi², Tetsuji Sawada³, Hiroko Nagafuchi⁴, Msataka Kuwana⁵, Mitsuhiro Takeno⁶ and Yoshiaki Ishigatsubo⁷, ¹Int Med/Rheumatol & Infec Dis, Kitasato Univ School of Med, Kanagawa, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³Internal Medicine 3, Tokyo Medical University, Tokyo, Japan, ⁴Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, ⁵Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁶Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan, ⁷Int Med & Clin Immunology, Yokohama City Grad Schl of Med, Yokohama, Japan
Background/Purpose: Chronic progressive neurological manifestations in Behcet's disease (BD) is characterized by progressive deterioration leading to disability either with or without a history of previous…
Abstract Number: 2496 • 2014 ACR/ARHP Annual Meeting
Predictors of ACR/EULAR Boolean and SDAI Remission in Patients with Established Rheumatoid Arthritis Treated with Anti-TNF: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Boulos Haraoui¹, Maqbool Sheriff², Majed Khraishi³, Michael Starr⁴, John Kelsall⁵, Milton Baker⁶, Regan Arendse⁷, Sanjay Dixit⁸, William Bensen⁹, Philip Baer¹⁰, Rafat Faraawi⁸, Emmanouil Rampakakis¹¹, John S. Sampalis¹¹, Susan Otawa¹², Allen J Lehman¹², Francois Nantel¹³ and May Shawi¹³, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ³Nexus Clinical Research, St John's, NF, Canada, ⁴Montreal General Hospital, Montreal, QC, Canada, ⁵The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁶University of Victoria, Victoria, BC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸McMaster University, Hamilton, ON, Canada, ⁹Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ¹⁰Private Practice, Scarborough, ON, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada
Background/Purpose Early achievement of remission is associated with improved clinical, functional and radiographic outcomes1. Recent recommendations of the Canadian Rheumatology Association dictate that treatment target…